Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00522990 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
A Phase 1 study, sponsored by Astex Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00522990 is a Phase 1 study that was terminated before completion, run by Astex Pharmaceuticals. The registered enrollment target is 48 participants.
The verdict
NCT00522990, a Phase 1 study, was terminated before completion, sponsored by Astex Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of AT9283 that can be given to patients who have ALL, AML, CML, high-risk myelodysplastic syndromes, or myelofibrosis with myeloid metaplasia. Researchers want to perform pharmacokinetic (PK) testing on blood to find out how quickly the study drug leaves the body and how the body breaks down the drug. The safety and effectiveness of this drug will also be studied.
Interventions
- DRUG AT9283
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00522990
The ClinicalTrials.gov registry entry for NCT00522990 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AT9283 is the first listed.
NCT00522990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00522990 about?
NCT00522990 is a clinical study titled "Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias". The goal of this clinical research study is to find the highest tolerable dose of AT9283 that can be given to patients who have ALL, AML, CML, high-risk myelodysplastic syndromes, or myelofibrosis with myeloid metaplasia. Researchers want to perform pharmacokinetic (PK) testing on blood to find out ...
What is the current status of trial NCT00522990?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2006-09. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00522990?
The interventions under investigation include: AT9283 (DRUG).
Who is sponsoring clinical trial NCT00522990?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.